Alison Moore
Directeur/Membre du Conseil chez CODEXIS, INC.
Fortune : 2 M $ au 30/06/2024
Profil
Actuellement, Alison Moore occupe le poste de directeur technique chez Allogene Therapeutics, Inc. Le Dr Moore est également membre du conseil d'administration de Codexis, Inc. Dans le passé, le Dr Moore a occupé le poste de vice-présidente principale du développement des processus chez Amgen, Inc. et de directrice de la chimie, de la fabrication et des contrôles chez Genentech, Inc. Alison Moore a obtenu un doctorat et un diplôme de premier cycle à l'université de Manchester.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 22/03/2023 | 670 173 ( 0,32% ) | 2 M $ | 30/06/2024 | |
CODEXIS, INC.
0,14% | 11/06/2024 | 98 696 ( 0,14% ) | 305 958 $ | 30/06/2024 |
Postes actifs de Alison Moore
| Sociétés | Poste | Début |
|---|---|---|
| CODEXIS, INC. | Directeur/Membre du Conseil | 16/06/2020 |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Directeur/Membre du Conseil | - |
Anciens postes connus de Alison Moore
| Sociétés | Poste | Fin |
|---|---|---|
| ALLOGENE THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 28/04/2023 |
| AMGEN INC. | Corporate Officer/Principal | 01/06/2018 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Conseiller Juridique Général | 01/01/2006 |
Formation de Alison Moore
| The University of Manchester | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| ALLOGENE THERAPEUTICS, INC. | Health Technology |
| CODEXIS, INC. | Process Industries |
| Entreprise privées | 2 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
